Ridaforolimus in Treatment of Sarcoma-SUCCEED (Sarcoma Multi-Center Clinical Eval. of the Efficacy of Ridaforolimus)

This study is currently recruiting participants.

Verified by Ariad Pharmaceuticals, November 2009

First Received: September 28, 2007 Last Updated: November 13, 2009 History of Changes

Sponsor:	Ariad Pharmaceuticals
Collaborator:	Merck
Information provided by:	Ariad Pharmaceuticals
ClinicalTrials.gov Identifier:	NCT00538239

Purpose

The purpose of this study is to determine whether maintenance therapy with oral AP23573 (ridaforolimus), by preventing and controlling tumor growth for a prolonged period of time in patients with metastatic soft-tissue or bone sarcomas responding to chemotherapy, will result in clinically significant improvement in progression-free survival as compared to oral placebo.

Condition	Intervention	Phase
Metastatic Soft-Tissue Sarcomas Metastatic Bone Sarcomas	Drug: ridaforolimus Drug: Placebo	Phase III

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Placebo Control, Parallel Assignment
Official Title:	A Pivotal Trial to Determine the Efficacy and Safety of AP23573 When Administered as Maintenance Therapy to Patients With Metastatic Soft-Tissue or Bone Sarcomas

Resource links provided by NLM:

MedlinePlus related topics: Cancer Soft Tissue Sarcoma

Drug Information available for: AP 23573

U.S. FDA Resources

Further study details as provided by Ariad Pharmaceuticals:

Primary Outcome Measures:

Progression-free Survival [ Time Frame: Duration of the study ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Overall survival [ Time Frame: Duration of the study ] [ Designated as safety issue: No ]
Anti-tumor response [ Time Frame: Duration of the study ] [ Designated as safety issue: No ]
Change in cancer-related symptoms [ Time Frame: Duration of the study ] [ Designated as safety issue: No ]
Safety and tolerability [ Time Frame: 18 months ] [ Designated as safety issue: Yes ]

Estimated Enrollment:	650
Study Start Date:	September 2007
Estimated Study Completion Date:	June 2014
Estimated Primary Completion Date:	June 2014 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Ridaforolimus: Experimental	Drug: ridaforolimus 40 mg, Oral, QDx5 (five consecutive days each week followed by two day holiday) until disease progression
Placebo: Placebo Comparator	Drug: Placebo Placebo

Eligibility

Ages Eligible for Study:	13 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Confirmed diagnosis of metastatic soft-tissue or bone sarcoma
Ongoing favorable outcome after a minimum of 4 cycles of prior chemotherapy for metastatic disease
ECOG performance status of 0 or 1
Age ≥13 years
Adequate organ and bone marrow function
Completed prior chemotherapy with last dose received at least 3 and up to 12 weeks prior to randomization

Exclusion Criteria:

Prior therapy with rapamycin or rapamycin analogs
Ongoing toxicity associated with prior anticancer therapy
Another primary malignancy within the past three years
Concomitant medications that induce or inhibit CYP3A
Significant, uncontrolled cardiovascular disease

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00538239

Contacts

Contact: Toll-Free Phone Number (US callers only)	877-621-2302
Contact: International callers	1-617-621-2302

Show 174 Study Locations

Sponsors and Collaborators

Ariad Pharmaceuticals

Merck

Investigators

Study Director:

ARIAD Medical Monitor

ARIAD Pharmaceuticals, Inc. 617-494-0400

More Information

Additional Information:

Related Info This link exits the ClinicalTrials.gov site

No publications provided

Responsible Party:	ARIAD Pharmaceuticals, Inc. ( Frank Haluska, M.D. )
Study ID Numbers:	AP23573-07-302
Study First Received:	September 28, 2007
Last Updated:	November 13, 2009
ClinicalTrials.gov Identifier:	NCT00538239 History of Changes
Health Authority:	United States: Food and Drug Administration

Additional relevant MeSH terms:

Sirolimus
Anti-Infective Agents
Neoplasms by Histologic Type
Immunologic Factors
Antineoplastic Agents
Physiological Effects of Drugs
Antibiotics, Antineoplastic
Immunosuppressive Agents

Pharmacologic Actions
Anti-Bacterial Agents
Neoplasms, Connective and Soft Tissue
Neoplasms
Therapeutic Uses
Antifungal Agents
Sarcoma

ClinicalTrials.gov processed this record on November 20, 2009